Internship

2025 Intern

Materials Planning

Posted on 10/10/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Norwood, MA, USA

Summer internship opportunity in Norwood, MA from June 2, 2025 – August 15, 2025.

Category
Inventory Management
Supply Chain Management
Operations & Logistics
Required Skills
Inventory Management
SAP Products
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Current student enrolled in a Bachelor’s in Supply Chain, Science, Engineering or Economics/Finance
  • Proficiency in Microsoft Excel is a must
  • Outstanding communication skills (verbal and written) to effectively collaborate and communicate with senior CMC Management in a dynamic, cross-functional matrix environment
Responsibilities
  • Execute MRP using SAP to plan raw material requirements weekly by defining appropriate MRP parameters, and executing requirements planning for both BOM driven and replenishment of all INT planned materials
  • Escalation of risk through management when identified and working through cross functional resolution of the issue. Working closely with vendor-facing partner teams to drive vendor resolution as required.
  • Problem solving MRP and purchasing issues with BOM owners, production planning, and manufacturing. Ultimately determining root cause and correcting MRP signals
  • Key team member to facilitate raw material projects and NPI, ensuring all demand changes are captured appropriately and material is introduced with one valid purchasing plan
  • Provide guidance to supply chain best practice in multi-site/CMO planning environment. Ensuring tactical raw material readiness for new projects as part of master project plan
  • Review updates to master production forecasts to assess raw material and budget impacts
  • Responsible for performance to material planning KPIs – including inventory target levels and safety stock adherence, on time quality release of incoming materials
  • Ad hoc data analysis for raw material planning as required

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the speed and efficiency of drug discovery and manufacturing. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of health conditions.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

15%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE